MCM
PCRX icon

Mazama Capital Management’s Pacira BioSciences PCRX Stock Holding History

Mazama Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,277
Closed -$558K – 304
2015
Q1 		$558K Sell
6,277
-2,614
-29% -$265K 0.11% 181
2014
Q4 		$788K Buy
+8,891
New +$841K 0.18% 153

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mazama Capital Management's PCRX Position: Q2 2015 in Review

Mazama Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2015, closing a stake of 6,277 shares — an estimated $558K sold.

Mazama Capital Management first reported a position in PCRX in Q4 2014 and held it in 2 quarters. The position peaked at $788K in Q4 2014. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

  • Mazama Capital Management reported no remaining Pacira BioSciences position as of Q2 2015 after selling out during the quarter.
  • Mazama Capital Management sold 6,277 Pacira BioSciences shares in Q2 2015, an estimated $558K.
  • Mazama Capital Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 2 quarters.
  • Mazama Capital Management's Pacira BioSciences position peaked at $788K in Q4 2014.
  • 187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on Mazama Capital Management's 13F filing for Q2 2015, filed 24 Aug 2015.